Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06793059 · ClinicalTrials.gov registry record · NA

Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD)

A NA study of Aneurysm, sponsored by Jacobs institute.

Recruiting
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT06793059 is a NA study of Aneurysm that is actively recruiting participants, run by Jacobs institute. The registered enrollment target is 10 participants, below the 17,095-participant average among 6 other Aneurysm trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06793059, a NA study of Aneurysm, is actively recruiting participants, sponsored by Jacobs institute.

RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The Jacobs Institute is participating in a study designed to collect prospective clinical evidence to evaluate the approved use of the Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with wide-necked intracranial aneurysms

Conditions Studied

Interventions

  • DEVICE SHIELD

Study Locations (1)

New York

  • Jacobs Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2025-01-01
Est. Completion 2027-01-01
Phase NA

Sponsor

Jacobs institute

5 total trials

What the Registry Record Tells You About NCT06793059

The ClinicalTrials.gov registry entry for NCT06793059 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 17,095-participant average among 6 other Aneurysm trials with a reported enrollment target (100% lower). The listed sponsor is Jacobs institute, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Aneurysm appearing as the primary indexed condition, and to 1 intervention - of which SHIELD is the first listed.

NCT06793059 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06793059 about?

NCT06793059 is a clinical study titled "Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD)". The Jacobs Institute is participating in a study designed to collect prospective clinical evidence to evaluate the approved use of the Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with wide-necked intracranial aneurysm...

What is the current status of trial NCT06793059?

This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2025-01-01. Estimated completion is 2027-01-01.

What conditions does trial NCT06793059 study?

This clinical trial studies the following conditions: Aneurysm.

What interventions are being tested in trial NCT06793059?

The interventions under investigation include: SHIELD (DEVICE).

Who is sponsoring clinical trial NCT06793059?

This trial is sponsored by Jacobs institute, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06793059 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aneurysm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.